RAPT Insider Trading

Insider Ownership Percentage: 6.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

RAPT Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at RAPT Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

RAPT Therapeutics Share Price & Price History

Current Price: $1.18
Price Change: Price Decrease of -0.045 (-3.69%)
As of 04/1/2025 04:59 PM ET

This chart shows the closing price history over time for RAPT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.22Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for RAPT Therapeutics (NASDAQ:RAPT)

99.09% of RAPT Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RAPT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$116Mbought$2.98MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
RAPT Therapeutics logo
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More on RAPT Therapeutics

Today's Range

Now: $1.18
Low: $1.17
High: $1.25

50 Day Range

MA: $1.19
Low: $1.05
High: $1.56

52 Week Range

Now: $1.18
Low: $0.79
High: $9.65

Volume

618,614 shs

Average Volume

1,274,487 shs

Market Capitalization

$155.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of RAPT Therapeutics?

RAPT Therapeutics' top insider shareholders include:
  1. Dirk G Brockstedt (Insider)
  2. William Ho (Insider)
Learn More about top insider investors at RAPT Therapeutics.

Who are the major institutional investors of RAPT Therapeutics?

RAPT Therapeutics' top institutional investors include:
  1. Medicxi Ventures Management Jersey Ltd — 63.94%
  2. TCG Crossover Management LLC — 37.57%
  3. Orbimed Advisors LLC — 37.57%
  4. Foresite Capital Management VI LLC — 35.76%
  5. RTW Investments LP — 33.65%
  6. BVF Inc. IL — 26.42%
Learn More about top institutional investors of RAPT Therapeutics stock.

Which institutional investors are selling RAPT Therapeutics stock?

During the last quarter, RAPT stock was sold by these institutional investors:
  1. Column Group LLC
  2. Two Sigma Investments LP
  3. D. E. Shaw & Co. Inc.
  4. Millennium Management LLC
  5. Two Sigma Advisers LP
  6. Dimensional Fund Advisors LP
  7. Jane Street Group LLC
  8. Deutsche Bank AG

Which institutional investors are buying RAPT Therapeutics stock?

During the previous quarter, RAPT stock was bought by institutional investors including:
  1. Medicxi Ventures Management Jersey Ltd
  2. Orbimed Advisors LLC
  3. TCG Crossover Management LLC
  4. Foresite Capital Management VI LLC
  5. RTW Investments LP
  6. BVF Inc. IL
  7. Deep Track Capital LP
  8. Redmile Group LLC